Does the Common Type 2 Diabetes-Susceptibility Variant in the MTNR1B Gene Matter for Glycemic Control Among Patients on Antidiabetic Pharmacotherapy?

Mayo Clin Proc. 2021 May;96(5):1372-1374. doi: 10.1016/j.mayocp.2021.03.005.

Authors

Xiao Tan¹, Christian Benedict¹

Affiliation

¹ Department of Neuroscience (Sleep Science Lab, BMC), Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Sweden.

PMID: 33958070
DOI: 10.1016/j.mayocp.2021.03.005

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Biomarkers / blood
Blood Glucose / metabolism
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / diagnosis
Diabetes Mellitus, Type 2 / drug therapy
Diabetes Mellitus, Type 2 / genetics*
Female
Genetic Markers
Genetic Predisposition to Disease*
Genotyping Techniques
Humans
Hypoglycemic Agents / therapeutic use*
Male
Middle Aged
Polymorphism, Single Nucleotide*
Receptor, Melatonin, MT2 / genetics*
Treatment Outcome

Substances

Biomarkers
Blood Glucose
Genetic Markers
Hypoglycemic Agents
MTNR1B protein, human
Receptor, Melatonin, MT2